Weight Watchers adds Ozempic pill to Med+ diabetes treatment program
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/13/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Super Micro Computer establishes $1.25 billion stock sale agreement
- Wall Street ends higher as SpaceX's market debut dominates
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- SpaceX Shares Indicated To Open At $155
Weight Watchers Expands Med+ With Access to New Ozempic® pill (semaglutide)
May 1, 2026 8:05 AM EDTNEW YORK, May 01, 2026 (GLOBE NEWSWIRE) -- WW International, Inc. (NASDAQ: WW) (Weight Watchers), the global leader in science-backed weight management, announced that it will begin offering access to Novo Nordisks now available Ozempic® pill (semaglutide) through its Med+ offering and affiliated medical groups. The addition will give members a once-daily GLP-1 option for adults living with type 2 diabetes, further expanding Weight Watchers growing portfolio of oral GLP-1 treatments available through a clinically supported program designed to help members succeed.
Novo Nordisk first introduced Ozempic® in the U.S. as an... More
